REG - FIL Limited Allergan PLC - Form 8.3 - Abbvie Inc

AbbvieAnnouncement

12/05/2020 15:35

RNS Number : 6739M
  
FIL Limited
  
12 May 2020
  
 

Ap19
 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


FMR LLC and/or one or more of its direct or indirect subsidiaries
And
FIL Limited and/or one or more of its direct and indirect subsidiaries




Company dealt in


ABBVIE INC




Class of relevant security to which the dealings being disclosed relate (Note 2)


ORDINARY SHARES




Date of dealing


11-May-2020




2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


33,509,651                 2.26%


 




(2) Derivatives (other than options)


 


 




(3) Options and agreements to purchase/sell


 


 




Total


33,509,651                 2.26%


 



 
 
 
 
 
 
 



                                                                                      
THE ABOVE INCLUDES A TRANSFER IN OF 648,888 ORDINARY SHARES
                                                                                  
 
(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)




Class of relevant security:


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


 


 




 
(2) Derivatives (other than options)


 


 




 
(3) Options and agreements to purchase/sell


 


 




Total


 


 



 
 
 
 
 
 
 




 

Ap20
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




Purchase/Sale


Number of relevant securities


Price per unit (Note 5)




Purchase


900


84.49 USD/Share




Purchase


100


84.60 USD/Share




Purchase


800


84.72 USD/Share




Purchase


763


85.02 USD/Share




Purchase


75,017


85.06 USD/Share




Purchase


14,620


85.07 USD/Share




Sale


5,174


86.62 USD/Share




Sale


1,700


86.78 USD/Share




Sale


1,300


86.80 USD/Share




Sale


1,824


86.89 USD/Share




Sale


1,100


87.01 USD/Share




Sale


2,682


87.09 USD/Share




Sale


18,220


87.13 USD/Share




Purchase


600


87.70 USD/Share




Purchase


10,456


87.88 USD/Share




Purchase


6,959


87.90 USD/Share




Purchase


39,137


88.00 USD/Share




Purchase


17,285


88.14 USD/Share




Purchase


117,656


88.15 USD/Share




Purchase


48,366


88.20 USD/Share




Sale


7,942


86.61 USD/Share




Purchase


2


83.96 USD/Share




Purchase


2,871


86.33 USD/Share




Sale


56


86.35 USD/Share




Purchase


6


86.44 USD/Share




Sale


1


84.21 USD/Share




Sale


1


84.24 USD/Share




Sale


1


84.27 USD/Share




Sale


1


84.29 USD/Share




Sale


1


84.31 USD/Share




Sale


1


84.32 USD/Share




Sale


1


84.35 USD/Share




Sale


1


84.54 USD/Share




Sale


1


84.56 USD/Share




Sale


1


84.62 USD/Share




Sale


1


84.63 USD/Share




Sale


1


84.67 USD/Share




Sale


1


84.72 USD/Share




Sale


1


84.74 USD/Share




Sale


2


84.77 USD/Share




Sale


1


84.79 USD/Share




Sale


1


84.81 USD/Share




Sale


1


84.88 USD/Share




 
 
 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(Note 5)




 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 




Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 
relevant securities to which any derivative referred to on this form is referenced. 
If none, this should be stated.
 
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


12-May-2020




Contact name


Paul Clark




Telephone number


00353 1 223 1447




If a connected EFM, name of offeree/offeror with which connected


 




If a connected EFM, state nature of connection (Note 10)


 




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEKKBBBNBKDCPD